

Type	L #	Hits	Search Text	DBs	Time Stamp	Com ment s	Error Def initio n
1	BRS	L1	466 botulinum adj (toxin or neurotoxin)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:42		0
2	BRS	L2	81 clostridial adj (toxin or neurotoxin)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:43		0
3	BRS	L3	2 beratti adj (toxin or neurotoxin)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:44		0
4	BRS	L4	3 butyricum adj (toxin or neurotoxin)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:44		0
5	BRS	L6	19 tetani adj (toxin or neurotoxin)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:45		0
6	BRS	L7	494 1 or 2 or 3 or 4 or 6	USPAT; EPO; JPO; DERWENT	2004/01/12 16:46		0
7	BRS	L8	3 7 same modif\$7 same (substance adj P)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:54		0
8	BRS	L9	44 LHN	USPAT; EPO; JPO; DERWENT	2004/01/12 16:54		0
9	BRS	L10	1 LHN same (substance adj P)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:54		0
10	BRS	L11	0 (light adj chain) same (transloca\$3 adj domain) same (substance adj P)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:55		0

Type	L #	Hits	Search Text	DBs	Time Stamp	Com ment s	Error Defi nito n
11	BRS	L12	12 (light adj chain) same (heavy adj chain) same (substance adj P)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:56		0
12	BRS	L13	1 12 same (covalent\$2 or conjugate)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:57		0
13	BRS	L16	52 donovan adj stephen.in.	USPAT; EPO; JPO; DERWENT	2004/01/12 16:58		0
14	BRS	L17	9 16 and (substance adj p)	USPAT; EPO; JPO; DERWENT	2004/01/12 16:58		0
15	BRS	L18	9 16 and (substance adj p) and 7	USPAT; EPO; JPO; DERWENT	2004/01/12 16:59		0

=> d his

(FILE 'HOME' ENTERED AT 17:02:59 ON 12 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

17:03:19 ON 12 JAN 2004

- L1 22817 S BOTULINUM (W) (TOXIN OR NEUROTOXIN)
- L2 1439 S CLOSTRIDIAL (W) (TOXIN OR NEUROTOXIN)
- L3 1 S BERATTI (W) (TOXIN OR NEUROTOXIN)
- L4 40 S BUTYRICUM (W) (TOXIN OR NEUROTOXIN)
- L5 433 S TETANI (W) (TOXIN OR NEUROTOXIN)
- L6 24013 S L1 OR L2 OR L3 OR L4 OR L5
- L7 726 S L6 (P) MODIF?
- L8 99984 S SUBSTANCE P
- L9 0 S L7 (P) L8
- L10 85 S L6 (P) L8
- L11 6 S L10 (P) CONJUGATE
- L12 6 DUPLICATE REMOVE L11 (0 DUPLICATES REMOVED)
- L13 0 S LHN (P) (SUBSTANCE P)
- L14 5 S (LIGHT CHAIN) (P) (HEAVY CHAIN) (P) (SUBSTANCE P)
- L15 0 S L14 (P) (CONJUAGE OR COVALENT? OR LINK?)
- L16 1 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
- L17 62 S DONOVAN STEPHEN/AU
- L18 5 S L17 AND L10
- L19 5 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)
- L20 0 S L17 AND L14

FILE 'MEDLINE' ENTERED AT 17:03:19 ON 12 JAN 2004

FILE 'CAPLUS' ENTERED AT 17:03:19 ON 12 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:03:19 ON 12 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:03:19 ON 12 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:03:19 ON 12 JAN 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 17:03:19 ON 12 JAN 2004

=> s botulinum (w) (toxin or neurotoxin)
L1 22817 BOTULINUM (W) (TOXIN OR NEUROTOXIN)

=> s clostridial (w) (TOXIN OR NEUROTOXIN)
L2 1439 CLOSTRIDIAL (W) (TOXIN OR NEUROTOXIN)

=> s beratti (w) (TOXIN OR NEUROTOXIN)
L3 1 BERATTI (W) (TOXIN OR NEUROTOXIN)

=> s butyricum (w) (TOXIN OR NEUROTOXIN)
L4 40 BUTYRICUM (W) (TOXIN OR NEUROTOXIN)

=> s tetani (w) (TOXIN OR NEUROTOXIN)
L5 433 TETANI (W) (TOXIN OR NEUROTOXIN)

=> s l1 or l2 or l3 or l4 or l5
L6 24013 L1 OR L2 OR L3 OR L4 OR L5

=> s l6 (p) modif?
L7 726 L6 (P) MODIF?

=> s substance P
L8 99984 SUBSTANCE P

=> s l7 (p) l8
L9 0 L7 (P) L8

=> s l6 (p) l8
L10 85 L6 (P) L8

=> s l10 (p) conjugate
L11 6 L10 (P) CONJUGATE

=> duplicate remove l11
PROCESSING COMPLETED FOR L11
L12 6 DUPLICATE REMOVE L11 (0 DUPLICATES REMOVED)

=> d l11 1-6 ibib abs

L11 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:862780 CAPLUS
DOCUMENT NUMBER: 139:358792
TITLE: Botulinum toxin derivatives and methods to treat pain
associated with bone cancer
INVENTOR(S): Donovan, Stephen
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 489,667.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6641820	B1	20031104	US 2000-625098	20000725
WO 2002007759	A2	20020131	WO 2001-US21984	20010712

WO 2002007759 A3 20030103

W: AE, AG, AL, AM, AT, AZ, BA, BB, BG, BR, BY, BZ, C, CH, CN,
CO, CR, CU, CZ, DE, DR, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002037833 A1 20020328 US 2001-922093 20010803

US 6500436 B2 20021231

US 2002068699 A1 20020606

US 2001-938112 20010823

US 2000-489667 A2 20000119

US 2000-625098 A 20000725

PRIORITY APPLN. INFO.:

AB Methods for treating pain assocd. with bone tumor by administration to a patient of a therapeutically effective amt. of an agent are disclosed. The agent may include a ***clostridial*** ***neurotoxin*** component attached to a targeting moiety, wherein the targeting moiety is selected from the group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds. Specifically disclosed are ***conjugates*** of ***botulinum*** ***toxin*** components with ***substance*** ***p***.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:721252 CAPLUS

DOCUMENT NUMBER: 138:1236

TITLE: Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinum Toxin A Endopeptidase Fragment and Erythrina cristagalli Lectin

AUTHOR(S): Duggan, Michael J.; Quinn, Conrad P.; Chaddock, John A.; Purkiss, John R.; Alexander, Frances C. G.; Doward, Sarah; Fooks, Sarah J.; Friis, Lorna M.; Hall, Yper H. J.; Kirby, Elizabeth R.; Leeds, Nicola; Mouldsdale, Hilary J.; Dickenson, Anthony; Green, G. Mark; Rahman, Wahida; Suzuki, Rie; Shone, Clifford C.; Foster, Keith A.

CORPORATE SOURCE: Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SPR 0JG, UK

SOURCE: Journal of Biological Chemistry (2002), 277(38), 34846-34852

PUBLISHER: CODEN: JBCHA3; ISSN: 0021-9258

AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Clostridial neurotoxins potently and specifically inhibit neurotransmitter release in defined cell types. Here we report that a catalytically active deriv. (termed LHN/A) of the type A neurotoxin from Clostridium botulinum has been coupled to a lectin obtained from Erythrina cristagalli to form a novel conjugate. This conjugate exhibits an in vitro selectivity for nociceptive afferents compared with the anatomically adjacent spinal neurons, as assessed using in vitro primary neuronal culture systems to measure inhibition of release of neurotransmitters. Chem. conjugates prepd. between E. cristagalli lectin and either natively sourced LHN/A or recombinant LHN/A purified from Escherichia coli are assessed, and equivalence of the recombinant material are demonstrated. Furthermore, the dependence of inhibition of neurotransmitter release on the cleavage of SNAP-25 is demonstrated through the use of an endopeptidase-deficient LHN/A conjugate variant. The duration of action of inhibition of neurotransmitter released by the conjugate in vitro is assessed and is comparable with that obsd. with Clostridium botulinum neurotoxin. Finally, in vivo electrophysiol. shows that these in vitro actions have biol. relevance in that sensory transmission from nociceptive afferents through the spinal cord is significantly attenuated. These data demonstrate that the potent endopeptidase activity of clostridial neurotoxins can be selectively retargeted to cells of interest and that inhibition of release of neurotransmitters from a neuronal population of therapeutic relevance to the treatment of pain can be achieved.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:241331 CAPLUS
 DOCUMENT NUMBER: 136:2732
 TITLE: Clostridial toxin derivatives and methods for treating pain
 INVENTOR(S): Donovan, Stephen
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S.
 Ser. No. 625,098.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002037833	A1	20020328	US 2001-922093	20010803
US 6500436	B2	20021231		
US 6641820	B1	20031104	US 2000-625098	20000725
PRIORITY APPLN. INFO.:			US 2000-489667	A2 20000119
			US 2000-625098	A2 20000725

AB Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amt. of the agent are disclosed. The agent can include a clostridial neurotoxin, or a component or fragment or deriv. thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds. The agent comprises a botulinum toxin component covalently coupled to substance P.

L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:89857 CAPLUS
 DOCUMENT NUMBER: 136:145260
 TITLE: Clostridial toxin derivatives and methods for treating pain
 INVENTOR(S): Donovan, Stephen
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007759	A2	20020131	WO 2001-US21984	20010712
WO 2002007759	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6641820	B1	20031104	US 2000-625098	20000725
PRIORITY APPLN. INFO.:			US 2000-625098	A 20000725
			US 2000-489667	A2 20000119

AB Methods for treating a bone tumor, in particular pain assoc'd. with bone tumor, by administration to a patient of a therapeutically effective amt. of an agent are disclosed. The agent may include a clostridial neurotoxin component attached to a targeting moiety, wherein the targeting moiety is selected from the group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds.

L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:545729 CAPLUS
 DOCUMENT NUMBER: 135:132453
 TITLE: Clostridial neurotoxin derivatives attached to targeting moieties, and methods using them for treating pain
 INVENTOR(S): Donovan, Stephen
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053336	A1	20010726	WO 2001-US1529	20010117
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	

US 2002068699 A1 20020606 US 2001-938112 20010823

PRIORITY APPLN. INFO.: US 2000-489667 A 20000119

AB The invention provides agents for treating pain, methods for producing the agents, and methods for treating pain by administration to a patient of a therapeutically effective amt. of the agent. The agent can include a clostridial neurotoxin, or a component of fragment or deriv. thereof, attached to a targeting moiety, wherein the targeting moiety is selected from transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:249106 CAPLUS

DOCUMENT NUMBER: 130:276767

TITLE: Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

INVENTOR(S): Duggan, Michael John; Chaddock, John Andrew

PATENT ASSIGNEE(S): The Speywood Laboratory Limited, UK; Microbiological Research Authority

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9917806	A1	19990415	WO 1998-GB3001	19981007
			W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2306350	AA	19990415	CA 1998-2306350	19981007
AU 9893574	A1	19990427	AU 1998-93574	19981007
AU 741456	B2	20011129		
ZA 9809138	A	19990527	ZA 1998-9138	19981007
EP 996468	A1	20000503	EP 1998-946571	19981007
EP 996468	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001518522	T2	20011016	JP 2000-514674	19981007
AT 240747	E	20030615	AT 1998-946571	19981007

PRIORITY APPLN. INFO.: GB 1997-21189 A 19971008

WO 1998-GB3001 W 19981007

AB A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurons and thereby reduce or preferably prevent the transmission of afferent pain signals from peripheral to central pain fibers. They comprise a galactose-binding lectin linked to a deriv. of a clostridial neurotoxin. The deriv. of the clostridial neurotoxin comprises the L-chain, or a fragment thereof, which

includes the active proteolytic enzyme domain of the light (L) chain, linked to a mol. or domain w/ membrane-translocating activity. The agents may be used in or as pharmaceuticals for the treatment of pain, particularly chronic pain.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:02:59 ON 12 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:03:19 ON 12 JAN 2004

L1 22817 S BOTULINUM (W) (TOXIN OR NEUROTOXIN)
L2 1439 S CLOSTRIDIAL (W) (TOXIN OR NEUROTOXIN)
L3 1 S BERATTI (W) (TOXIN OR NEUROTOXIN)
L4 40 S BUTYRICUM (W) (TOXIN OR NEUROTOXIN)
L5 433 S TETANI (W) (TOXIN OR NEUROTOXIN)
L6 24013 S L1 OR L2 OR L3 OR L4 OR L5
L7 726 S L6 (P) MODIF?
L8 99984 S SUBSTANCE P
L9 0 S L7 (P) L8
L10 85 S L6 (P) L8
L11 6 S L10 (P) CONJUGATE
L12 6 DUPLICATE REMOVE L11 (0 DUPLICATES REMOVED)

=> s LHN (p) (substance P)

L13 0 LHN (P) (SUBSTANCE P)

=> s (light chain) (p) (heavy chain) (p) (substance P)

L14 5 (LIGHT CHAIN) (P) (HEAVY CHAIN) (P) (SUBSTANCE P)

=> s l14 (p) (conjugate or covalent? or link?)

L15 0 L14 (P) (CONJUGATE OR COVALENT? OR LINK?)

=> duplicate remove l14

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L14

L16 1 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)

=> d l16 1 ibib abs

L16 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 1998288285 MEDLINE
DOCUMENT NUMBER: 98288285 PubMed ID: 9624139
TITLE: Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I.
AUTHOR: Wolters P J; Raymond W W; Blount J L; Caughey G H
CORPORATE SOURCE: Department of Medicine and the Cardiovascular Research Institute, University of California, San Francisco, California 94143-0911, USA.
CONTRACT NUMBER: HL-07185 (NHLBI)
HL-24136 (NHLBI)
HL-54774 (NHLBI)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 Jun 19) 273 (25) 15514-20.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF060171
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 19980716
Last Updated on STN: 20000303
Entered Medline: 19980709

AB Dipeptidyl peptidase I (DPPI) is a cysteine protease found predominantly in myelomonocytic cells, cytotoxic T-cells, and mast cells. Recent studies identify an intracellular role for mast cell-DPPI (MC-DPPI) by activating prochymase and protryptase to their mature forms. To better define MC-DPPI and to explore the possibility of extracellular roles, we purified MC-DPPI from mastocytoma cells. We found the dog C2 mastocytoma cell line to be the richest source yet described for DPPI, purifying up to 200 microg of enzyme per g of cells. Dog MC-DPPI has an Mr of approximately 175,000 and consists of four subunits, each composed of a

propeptide, ***light*** ***chain***, and ***heavy*** ***chain***. The ***heavy*** ***chain*** is N-glycosylated and is heterogeneously processed to three different forms. NH₂-terminal sequences of the ***heavy*** ***chain*** and propeptide are identical to those predicted from a cDNA clone we sequenced from a mastocytoma cDNA library. The dog cDNA-derived sequence is 86% identical to that of human DPPI. Dog mastocytoma cells incubated with 12-O-tetradecanoylphorbol-13-acetate increase expression of MC-DPPI mRNA. MC-DPPI maintains its activity for dipeptide substrates at a neutral to alkaline pH. Cells stimulated with ionophore or ***substance*** ***p*** secrete MC-DPPI in parallel with the granule-associated mediators tryptase and histamine. Thus, dog mastocytoma cells secrete DPPI that is active at the pH of extracellular fluids, suggesting that MC-DPPI may act outside the cell.

=> s donovan stephen/au
L17 62 DONOVAN STEPHEN/AU

=> d his

(FILE 'HOME' ENTERED AT 17:02:59 ON 12 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
17:03:19 ON 12 JAN 2004

L1 22817 S BOTULINUM (W) (TOXIN OR NEUROTOXIN)
L2 1439 S CLOSTRIDIAL (W) (TOXIN OR NEUROTOXIN)
L3 1 S BERATTI (W) (TOXIN OR NEUROTOXIN)
L4 40 S BUTYRICUM (W) (TOXIN OR NEUROTOXIN)
L5 433 S TETANI (W) (TOXIN OR NEUROTOXIN)
L6 24013 S L1 OR L2 OR L3 OR L4 OR L5
L7 726 S L6 (P) MODIF?
L8 99984 S SUBSTANCE P
L9 0 S L7 (P) L8
L10 85 S L6 (P) L8
L11 6 S L10 (P) CONJUGATE
L12 6 DUPLICATE REMOVE L11 (0 DUPLICATES REMOVED)
L13 0 S LHN (P) (SUBSTANCE P)
L14 5 S (LIGHT CHAIN) (P) (HEAVY CHAIN) (P) (SUBSTANCE P)
L15 0 S L14 (P) (CONJUGATE OR COVALENT? OR LINK?)
L16 1 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L17 62 S DONOVAN STEPHEN/AU

=> s l17 and l10
L18 5 L17 AND L10

=> duplicate remove l18
PROCESSING COMPLETED FOR L18
L19 5 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> s l17 and l14
L20 0 L17 AND L14

=> d l19 1-5 ibib abs

L19 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:696303 CAPLUS
DOCUMENT NUMBER: 139:224458
TITLE: ***Botulinum*** ***toxin*** and
substance ***p*** components for treating
inflammation and pain
INVENTOR(S): ***Donovan, Stephen***
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003165541	A1	20030904	US 2002-82691	20020225

PRIORITY APPLN. INFO.: US 2002-82691 20020225

AB The present invention relates to methods for treating neurogenic inflammation pain. The methods include administering an effective amt. of a compn. which includes a ***botulinum*** ***toxin*** component

and a ***substance*** ***p*** component to a patient, thereby treating the neurogenic inflation pain.

L19 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:862780 CAPLUS

DOCUMENT NUMBER: 139:358792

TITLE: Botulinum toxin derivatives and methods to treat pain associated with bone cancer

INVENTOR(S): ***Donovan, Stephen***

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 489,667.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6641820	B1	20031104	US 2000-625098	20000725
WO 2002007759	A2	20020131	WO 2001-US21984	20010712
WO 2002007759	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002037833	A1	20020328	US 2001-922093	20010803
US 6500436	B2	20021231		
US 2002068699	A1	20020606	US 2001-938112	20010823
			US 2000-489667	A2 20000119
			US 2000-625098	A 20000725

PRIORITY APPLN. INFO.:

AB Methods for treating pain assocd. with bone tumor by administration to a patient of a therapeutically effective amt. of an agent are disclosed. The agent may include a ***clostridial*** ***neurotoxin*** component attached to a targeting moiety, wherein the targeting moiety is selected from the group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds. Specifically disclosed are conjugates of ***botulinum*** ***toxin*** components with ***substance*** ***p***.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:89857 CAPLUS

DOCUMENT NUMBER: 136:145260

TITLE: Clostridial toxin derivatives and methods for treating pain

INVENTOR(S): ***Donovan, Stephen***

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007759	A2	20020131	WO 2001-US21984	20010712
WO 2002007759	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6641820	B1	20031104	US 2000-625098	20000725
			US 2000-625098	A 20000725

PRIORITY APPLN. INFO.:

AB Methods for treating a bone tumor, in particular pain assocd. with bone tumor, by administration to a patient of a therapeutically effective amt. of an agent are disclosed. The agent may include a clostridial neurotoxin component attached to a targeting moiety, wherein the targeting moiety is selected from the group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds.

L19 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:241331 CAPLUS

DOCUMENT NUMBER: 136:273210

TITLE: Clostridial toxin derivatives and methods for treating pain

INVENTOR(S): ***Donovan, Stephen***

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 625,098.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002037833	A1	20020328	US 2001-922093	20010803
US 6500436	B2	20021231		
US 6641820	B1	20031104	US 2000-625098	20000725
PRIORITY APPLN. INFO.:			US 2000-489667	A2 20000119
			US 2000-625098	A2 20000725

AB Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amt. of the agent are disclosed. The agent can include a ***clostridial*** ***neurotoxin***, or a component or fragment or deriv. thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compds. which can be released from neurons upon the transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds. The agent comprises a ***botulinum*** ***toxin*** component covalently coupled to ***substance*** ***p***.

L19 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:545729 CAPLUS

DOCUMENT NUMBER: 135:132453

TITLE: Clostridial neurotoxin derivatives attached to targeting moieties, and methods using them for treating pain

INVENTOR(S): ***Donovan, Stephen***

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053336	A1	20010726	WO 2001-US1529	20010117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002068699	A1	20020606	US 2001-938112	20010823

PRIORITY APPLN. INFO.: US 2000-489667 A 20000119

AB The invention provides agents for treating pain, methods for producing the agents, and methods for treating pain by administration to a patient of a therapeutically effective amt. of the agent. The agent can include a clostridial neurotoxin, or a component of fragment or deriv. thereof, attached to a targeting moiety, wherein the targeting moiety is selected from transmission compds. which can be released from neurons upon the

transmission of pain signals by the neurons, and compds. substantially similar to the transmission compds.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:02:59 ON 12 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:03:19 ON 12 JAN 2004

L1 22817 S BOTULINUM (W) (TOXIN OR NEUROTOXIN)
L2 1439 S CLOSTRIDIAL (W) (TOXIN OR NEUROTOXIN)
L3 1 S BERATTI (W) (TOXIN OR NEUROTOXIN)
L4 40 S BUTYRICUM (W) (TOXIN OR NEUROTOXIN)
L5 433 S TETANI (W) (TOXIN OR NEUROTOXIN)
L6 24013 S L1 OR L2 OR L3 OR L4 OR L5
L7 726 S L6 (P) MODIF?
L8 99984 S SUBSTANCE P
L9 0 S L7 (P) L8
L10 85 S L6 (P) L8
L11 6 S L10 (P) CONJUGATE
L12 6 DUPLICATE REMOVE L11 (0 DUPLICATES REMOVED)
L13 0 S LHN (P) (SUBSTANCE P)
L14 5 S (LIGHT CHAIN) (P) (HEAVY CHAIN) (P) (SUBSTANCE P)
L15 0 S L14 (P) (CONJUGATE OR COVALENT? OR LINK?)
L16 1 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L17 62 S DONOVAN STEPHEN/AU
L18 5 S L17 AND L10
L19 5 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)
L20 0 S L17 AND L14

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	99.29	99.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.62	-7.62

STN INTERNATIONAL LOGOFF AT 17:13:14 ON 12 JAN 2004